These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36555190)

  • 21. Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.
    Pierce SR; Fang Z; Yin Y; West L; Asher M; Hao T; Zhang X; Tucker K; Staley A; Fan Y; Sun W; Moore DT; Xu C; Tsai YH; Parker J; Prabhu VV; Allen JE; Lee D; Zhou C; Bae-Jump V
    J Exp Clin Cancer Res; 2021 Feb; 40(1):61. PubMed ID: 33557912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
    Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
    Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells.
    Al Madhoun A; Haddad D; Al Tarrah M; Jacob S; Al-Ali W; Nizam R; Miranda L; Al-Rashed F; Sindhu S; Ahmad R; Bitar MS; Al-Mulla F
    Sci Rep; 2021 Jun; 11(1):11893. PubMed ID: 34088951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.
    Ralff MD; Jhaveri A; Ray JE; Zhou L; Lev A; Campbell KS; Dicker DT; Ross EA; El-Deiry WS
    Oncotarget; 2020 Oct; 11(42):3753-3769. PubMed ID: 33144917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK; Allen JE; Dicker DT; El-Deiry WS
    Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).
    Liguori NR; Sanchez Sevilla Uruchurtu A; Zhang L; Abbas AE; Lee YS; Zhou L; Azzoli CG; El-Deiry WS
    Am J Cancer Res; 2022; 12(2):729-743. PubMed ID: 35261798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis.
    Di Cristofano FR; Fong MW; Huntington KE; Carneiro BA; Zhou L; El-Deiry WS
    Am J Cancer Res; 2023; 13(1):307-325. PubMed ID: 36777502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
    Atkins SLP; Greer YE; Jenkins S; Gatti-Mays ME; Houston N; Lee S; Lee MJ; Rastogi S; Sato N; Burks C; Annunziata CM; Lee JM; Nagashima K; Trepel JB; Lipkowitz S; Zimmer AS
    Oncologist; 2023 Oct; 28(10):919-e972. PubMed ID: 37279797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity.
    Jin ZZ; Wang W; Fang DL; Jin YJ
    Biochem Biophys Res Commun; 2016 Sep; 478(4):1515-20. PubMed ID: 27565731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
    Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
    Allen JE; Prabhu VV; Talekar M; van den Heuvel AP; Lim B; Dicker DT; Fritz JL; Beck A; El-Deiry WS
    Cancer Res; 2015 Apr; 75(8):1668-74. PubMed ID: 25681273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of
    Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF
    Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ONC201 Suppresses Neuroblastoma Growth by Interrupting Mitochondrial Function and Reactivating Nuclear ATRX Expression While Decreasing MYCN.
    Wu JC; Huang CC; Wang PW; Chen TY; Hsu WM; Chuang JH; Chuang HC
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro.
    Zhang J; Luo B; Sui J; Qiu Z; Huang J; Yang T; Luo Y
    Biochem Pharmacol; 2022 Oct; 204():115232. PubMed ID: 36030831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
    Ames E; Hallett WH; Murphy WJ
    Clin Exp Immunol; 2009 Mar; 155(3):504-13. PubMed ID: 19220837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells.
    Lim B; Peterson CB; Davis A; Cho E; Pearson T; Liu H; Hwang M; Ueno NT; Lee J
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitochondrial Matrix Protease ClpP Agonists Inhibit Cancer Stem Cell Function in Breast Cancer Cells by Disrupting Mitochondrial Homeostasis.
    Greer YE; Hernandez L; Fennell EMJ; Kundu M; Voeller D; Chari R; Gilbert SF; Gilbert TSK; Ratnayake S; Tang B; Hafner M; Chen Q; Meerzaman D; Iwanowicz E; Annunziata CM; Graves LM; Lipkowitz S
    Cancer Res Commun; 2022 Oct; 2(10):1144-1161. PubMed ID: 36388465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer.
    Staley A; Tucker K; Yin Y; Zhang X; Fan Y; Zhang Y; Fang Z; Sun W; Suo H; Zhao X; Zhao Z; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
    Am J Cancer Res; 2021; 11(11):5374-5387. PubMed ID: 34873466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro.
    Fang Z; Wang J; Clark LH; Sun W; Yin Y; Kong W; Pierce SR; West L; Sullivan SA; Tran AQ; Prabhu VV; Zhou C; Bae-Jump V
    Am J Cancer Res; 2018; 8(8):1551-1563. PubMed ID: 30210923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells.
    Geiß C; Witzler C; Poschet G; Ruf W; Régnier-Vigouroux A
    Eur J Immunol; 2021 May; 51(5):1246-1261. PubMed ID: 33442873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.